Guidelines for the diagnosis of bisphosphonate-related osteonecrosis of the jaw (BRONJ)

Clinical Cases in Mineral and Bone Metabolism

Volumn 4, Issue 1, 2007, Pages 37-42

  Ruggiero, Salvatore L ^a,b,c  

^a STONY BROOK UNIVERSITY   (United States)

^b LONG ISLAND JEWISH MEDICAL CENTER   (United States)

^c New York Center for Orthognathic and Maxillofacial Surgery   (United States)

Author keywords

Bisphosphonate; Bisphosphonate associated osteonecrosis of the jaw; Bisphosphonate related osteonecrosis of the jaw; BRONJ; Osteonecrosis of the jaw

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE;

BONE BIOPSY; BONE NECROSIS; CLINICAL FEATURE; HUMAN; JAW; MORBIDITY; OSTEOPOROSIS; PRACTICE GUIDELINE; RISK FACTOR; SHORT SURVEY;

EID: 34250311671     PISSN: 17248914     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Short Survey

References (48)

1. Hortobagyi GN, Theriualt RL, Lipton A, et al. Long-term prevention of skeletal complications of metastatic breast cancer with pamidronate. J Clin Oncol. 1998;16:2038.
2. van Holten-Verzantvoort ATM, Kroon HM, Bijvoet OLM, et al. Palliative pamidronate treatment in patients with bone metastases from breast cancer. J Clin Oncol. 1993;11:491-8.
3. Berensen JR, Lichtenstein A, Porter L, et al. Long term pamidronate treatment of advanced multiple myeloma patients reduces skeletal events. J Clin Oncol. 1998;16:593.
4. Hortobagyi GN, Theriualt RL, Porter L, et al. Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastasis. N Engl J Med. 1996;335:1785-92.
5. Berensen JR, Lichtenstein A, Porter L, et al. Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma. N Engl J Med. 1996;334:448-93.
6. Theriualt RL, Lipton A, Hortobagyi ON, et al. Pamidronate reduces skeletal morbidity in women with advanced breast cancer and lytic lesions: a randomized placebo-controlled trial. J Clin Oncol. 1999; 17:846.
7. Michaelson MD, Smith MR. Bisphosphonates for the treatment and prevention of bone metastases. J Clin Oncol. 2005;23:8219-8224.
8. Conte P, Coleman R. Bisphosphonates in the treatment of skeletal metastases. Semin Oncol. 2004;31:59-63.
9. Hillner BE, Ingle JN, Berenson JR, et al. American Society of Clinical Oncology guideline on the role of bisphosphonates in breast cancer. J Clin Oncol. 2000;18:1378-91.
10. Berenson JR, Hillner BE, Kyle RA, et al. American Society of Clinical Oncology clinical practice guidelines: the role of bisphosphonates in multiple myeloma. J Clin Oncol. 2002;20:3719-36.
11. Chestnut C, Majumdar S, Gardner J. Assessment of bone quality, quantity and turnover with multiple methodologies at multiple skeletal sites. Adv Exp Med Biol. 2001;496:95-7.
12. Guyatt GH, Cranney A, Griffith L. Summary of meta-analysis of therapies for postmenopausal osteoporosis and the relationship between bone density and fractures. Endocrinol Metab Clin North Am. 2002;31:659-79.
13. Black DM, Cummings SR, Karpf DB, et al. Randomized trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Lancet. 1996;348:1535-41.
14. Hosking D, Chilvers CED, Christiansen C, et al. Prevention of bone loss with alendronate in postmenopausal women under 60 years of age. Early Postmenopausal Intervention Cohort Suty Group. N Engl J Med. 1998;338:485-92.
15. Ravn P, Bidstrup M, Wasnick RD, et al. Alendronate and estrogen-progestin in the long-term prevention of bone loss: four-year results from the early postmenopausal intervention cohort study randomized, controlled trial. Ann Intern Med. 1999;131:935-42.
16. McClung MR, Geusens P, Miller PD, et al. Effect of risedronate on the risk of hip fracture in elderly women. N Engl J Med. 2001; 344:333-40.
17. Miller P, Roux C, McClung M, et al. Risedronate reduces hip fractures in patients with low femoral neck bone mineral density [abstract]. Arthritis Rheum. 1999;42(Suppl 9):S287.
18. Mehrotra B, Fantasia J, Nissel-Horowitz S, et al. Osteonecrosis of the maxilla: an unusual complication of prolonged bisphosphonate therapy. A case report. [Abstract 3194] Proceedings Am Soc Clin Oncol. 2003;22:795.
19. Rosenberg TJ, Ruggiero SL. Osteonecrosis of the jaws associated with the use of bisphosphonates. [Abstract] J Oral Maxillofac Surg. 2003; 61(suppl 1:)60.
20. Ruggiero SL, Mehrotra B, Rosenberg TJ, et al. Osteonecrosis of the jaws associated with the use of bisphosphonates: a review of 63 cases. J Oral Maxillofac Surg. 2004;62:527-34.
21. Greenberg MS. Intravenous bisphosphonates and osteonecrosis. [Editorial] Oral Surg Oral Med Oral Pathol Oral Radiol Endond. 2004; 93:259-60.
22. Vannucchi AM, Ficarra G, Antonioli E, et al. Osteonecrosis of the jaw associated with zoledronate therapy in a patient with multiple myeloma. Br Hematol. 2005;128:738.
23. Migliorati CA, Schubert MM, Petersen DE, et al. Bisphosphonate-associated osteonecrosis of mandibular and maxillary bone. An emerging oral complication of supportive cancer therapy. Cancer. 2005;104:83-93.
24. Marx RE, Sawatari Y, Fortin M, et al. Bisphosphonate-induced exposed bone (Osteonecrosis\Osteopetrosis) of the jaws: Risk factors, recognition, prevention and treatment. JOMS. 2005;63:1567-1575.
25. Mehrotra B, Ruggiero SL. Bisphosphonate related osteonecrosis (BRON) of the jaw: single institutional update. Blood. 2005;106: Abstract #291
26. Melo MD, Obeid G. Osteonecrosis of the jaws in patients with a history of receiving bisphosphonate therapy. JADA. 136:1675-1681.
27. Ruggiero SL, Fantasia J, Carlson E. Bisphosphonate-related osteonecrosis of the jaw: background and guidelines for diagnosis, staging and management: Oral Surg Oral Med Oral Path Oral Rad Endod. 2006 Oct;102(4):433-441.
28. Van Poznak C, Ward, B. Osteonecrosis of the jaw. Current Opinion Orthopaedics. 2006;17:1-7.
29. Gibbs SD, O'Grady J, Seymour JF, et al. Bisphosphonate-induced osteonecrosis of the jaws requires early detection and intervention. MJA. 2005;183:549-550.
30. Purcell PM, Boyd IW. Bisphosphonates and osteonecrosis of the jaw. MJA. 2005;182:417-418.
31. Bilezikian JP. Osteonecrosis of the jaw- Do bisphosphonates pose a risk? N Engl J Med. 2006;355:2278-2281.
32. Migliorati CA, Casiglia J, Epstein J, et al. Managing the care of patients with bisphosphonate-associated osteonecrosis. JADA. 2005; 136:1658-68.
33. Dimopoulos M, Kastritis E, Moulopoulos LA, et al. The incidence of osteonecrosis of the jaw in patients with multiple myeloma who receive bisphosphonates depends on the type of bisphosphonate. Blood. 2005;106:Abstract #637
34. Tosi P, Zamagni E, Cangini D, et al. Bisphosphonates and osteonecrosis of the jaws: incidence in a homogeneous series of patients with newly diagnosed multiple myeloma treated with zolendronic acid. Blood. 2005;106:Abstract #3461
35. Pozzi S, Marcheselli R, Sacchi S, et al. Analysis of frequency and risk factors for developing bisphosphonate associated necrosis of the jaw. Blood. 2005;106:Abstract #5057.
36. Gallucci C, Agrillo A, Iannetti G, et al. Possible role of ozone therapy in the treatment of osteonecrosis of the jaw in multiple myeloma patients. Blood. 2005;106:Abstract # 3460.
37. Cafro AM, Barbarano LA, Andriani A, et al. Osteonecrosis of the jaw associated with chronic bisphosphonate therapy: an Italian experience. Blood. 2005;106:Abstract #5152.
38. Badros A, Weikel D, Salama A, et al. Ostonecrosis of the jaw in multiple myeloma patients: clinical features and risk factors. J Clin Oncol. 2006;24:945-952.
39. Durie BGM, Katz M, Crowley J. Osteonecrosis of the jaw and bisphosphonates. [Letter] N Engl J Med. 2005;353:99.
40. Woo SB, Hellstein JW, Kalmar JR. Narrative review: bisphosphonates and osteonecrosis of the jaws. Ann Intern Med. 2006 May 16;144(10):753-61. Review. Erratum in: Ann Intern Med. 2006 Aug 1;145(3):235.
41. Hoff AO, Toth BB, Altundag K, et al. Osteonecrosis of the jaw in patients receiving intravenous bisphosphonate therapy. J Clin Oncol. 2006 ASCO Annual Meeting Proceedings (post meeting edition). 2006;24:8528. Available at: http://meeting.jco.org/cgi/content/abstract/24/18_suppl/8528
42. Cheng A, Mavrokokki A, Carter G, et al. The dental implications of bisphosphonates and bone disease. Aust Dent J Med Suppl. 2005; 50:4.
43. American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaws. http://www.aaoms.org/docs/ position_papers/osteonecrosis.pdf. Accessed January 2007.
44. Odvina CV, Zerwekh JE, Sudhaker R, et al. Severely suppressed bone turnover: a potential complication of Alendronate therapy. J Clin Endocrinol Metab. 2005;90:1294-1301.
45. Black DM, Schwartz AV, Ensrud KE, et al. Effects of continuing or stopping alendronate after 5 years of treatment. The Fracture Intervention Trial Long-term Extension (FLEX): A randomized trial. JAMA. 2006;296:2927-2938.
46. Ott SM. Long-term safety of bisphosphonates (Editorial). J Clin Endocrinol Metab. 2005;90:1897-99.
47. Colon-Emeric CS. Ten vs five years of bisphosphonate treatment for postmenopausal osteoporosis. Enough of a good thing (Editorial). JAMA. 2006;296:2968-2969.
48. Lacy MQ, Dispenzieri A, Gertz MA, et al. Mayo clinic consensus statement for the use of bisphosphonates in multiple myeloma. Mayo Clin Proc. 2006;81:1047-53.